Xgenera

Executive Summary

Xgenera is a UK-based biotechnology company dedicated to transforming early disease detection through innovative diagnostic technologies. Founded in 2019 and headquartered in Oxford, the company’s lead program, miONCO, is a multi-cancer early detection (MCED) test designed to identify up to 12 different cancer types from a single sample. By enabling earlier diagnosis, Xgenera aims to significantly improve survival outcomes and quality of life for patients. The company operates in the diagnostics sector and is privately held, with no disclosed funding or valuation details to date. Despite its early stage, Xgenera has a clear mission to address a critical unmet need in oncology. The miONCO test has the potential to disrupt the cancer screening market by offering a comprehensive, non-invasive solution. The company is expected to advance its clinical development program, with upcoming milestones likely including the initiation of a pivotal clinical trial, publication of validation data, and strategic partnership announcements. If successful, Xgenera could position itself as a key player in the rapidly growing MCED space, which is attracting significant interest from investors and healthcare providers globally.

Upcoming Catalysts (preview)

• Q3 2026Initiation of pivotal clinical trial for miONCO70% success
• Q4 2026Publication of clinical validation data65% success
• H2 2026Strategic partnership for commercialization50% success